Afficher la couverture 'Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients | Azzopardi, Nicolas' en grand format
/5

0 avis

Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients

Archive ouverte

Azzopardi, Nicolas | Lecomte, Thierry | Ternant, David | Boisdron-Celle, Michelle | Piller, Friedrich | Morel, Alain | Gouilleux-Gruart, Valérie | Vignault-Desvignes, Céline | Watier, Hervé | Gamelin, Erick | Paintaud, Gilles

Edité par CCSD ; American Association for Cancer Research -

International audience. An ancillary phase II study was conducted to study interindividual variability in cetuximab pharmacokinetics and its influence on progression-free survival (PFS) in metastatic colorectal cancer patients cotreated with irinotecan and 5-fluorouracil.

Consulter en ligne

Suggestions

Du même auteur

Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab

Archive ouverte | Rollin, Jérôme | CCSD

International audience. Aim: The efficacy of a cetuximab-based regimen used to treat metastatic colorectal cancer (mCRC) could be influenced by VEGFA polymorphisms. Materials & methods: We studied the effects of fiv...

Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients

Archive ouverte | Azzopardi, Nicolas | CCSD

International audience

An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab

Archive ouverte | Ceze, Nicolas | CCSD

International audience. Cetuximab is anti-epidermal growth factor receptor monoclonal antibody used in the treatment of colorectal and head and neck cancers. Part of the interindividual differences in response may b...

Chargement des enrichissements...